50 related articles for article (PubMed ID: 8679973)
1. [Does the administration of a high dose of a paramagnetic contrast medium (Gadovist) improve the diagnostic value of magnetic resonance tomography in glioblastomas?].
Hartmann M; Forsting M; Jansen O; Albert FK; Balzer T; Sartor K
Rofo; 1996 Feb; 164(2):119-25. PubMed ID: 8679973
[TBL] [Abstract][Full Text] [Related]
2. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
3. [Oral contrast media for magnetic resonance tomography of the abdomen. III. Initial patient research with gadolinium-DTPA].
Claussen C; Kornmesser W; Laniado M; Kaminsky S; Hamm B; Felix R
Rofo; 1988 Jun; 148(6):683-9. PubMed ID: 2837806
[TBL] [Abstract][Full Text] [Related]
4. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
[TBL] [Abstract][Full Text] [Related]
5. [Gadolinium-DTPA as an oral contrast medium for magnetic resonance tomography of the pancreas].
Neumann K; Kaminsky S; Gogoll M; Clauss W; Langer M; Felix R
Rofo; 1991 Mar; 154(3):262-8. PubMed ID: 1849293
[TBL] [Abstract][Full Text] [Related]
6. [The diagnosis of bladder carcinomas by NMR tomography: an improvement with Gd-DTPA?].
Sparenberg A; Hamm B; Hammerer P; Samberger V; Wolf KJ
Rofo; 1991 Aug; 155(2):117-22. PubMed ID: 1878537
[TBL] [Abstract][Full Text] [Related]
7. [Oral contrast medium for magnetic resonance tomography of the abdomen. II. Phase I clinical testing of gadolinium-DTPA].
Kornmesser W; Laniado M; Hamm B; Clauss W; Weinmann HJ; Schulz E; Wolf KJ; Felix R
Rofo; 1987 Nov; 147(5):550-6. PubMed ID: 2825293
[TBL] [Abstract][Full Text] [Related]
8. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
[TBL] [Abstract][Full Text] [Related]
9. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
Bauner KU; Reiser MF; Huber AM
Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
[TBL] [Abstract][Full Text] [Related]
11. [NMR tomography of the liver with the new contrast agent Gd-BOPTA. The results of an in-vivo phase-I test].
Vogl TJ; Pegios W; Waitzinger J; Pirovano G; Balzer J; Lissner J
Rofo; 1992 May; 156(5):465-70. PubMed ID: 1596551
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
14. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
16. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy.
van der Molen AJ; Bellin MF
Eur J Radiol; 2008 May; 66(2):168-74. PubMed ID: 18372137
[TBL] [Abstract][Full Text] [Related]
17. [Optimization of gadolinium-DTPA dose: an inter-individual study of patients with intracranial tumors].
Schubeus P; Schörner W; Haustein J; Hosten N; Niendorf HP; Felix R
Rofo; 1990 Jul; 153(1):29-35. PubMed ID: 2166308
[TBL] [Abstract][Full Text] [Related]
18. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.
Thilmann O; Larsson EM; Björkman-Burtscher IM; Ståhlberg F; Wirestam R
J Magn Reson Imaging; 2005 Nov; 22(5):597-604. PubMed ID: 16200539
[TBL] [Abstract][Full Text] [Related]
19. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver].
Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E
Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853
[TBL] [Abstract][Full Text] [Related]
20. [Preoperative staging of bladder carcinomas with Gd-DTPA-supported dynamic magnetic resonance tomography. Comparison with plain and Gd-DTPA-supported spin-echo sequences].
Venz S; Hosten N; Ilg J; Mäurer J; Podrabsky P; Fedel M; Ebert T; Nagel R
Rofo; 1996 Mar; 164(3):218-25. PubMed ID: 8672777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
